Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

A blood biomarker for monitoring response to anti-EGFR therapy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Different expression of EZH2, BMI1 and Ki67 in low and high grade neuroendocrine tumors of the lung

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Tumor cell MT1-MMP is dispensable for osteosarcoma tumor growth, bone degradation and lung metastasis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Limited diagnostic utility of Chromogranin A measurements in workup of neuroendocrine tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Blocking of efflux transporters in rats improves translational validation of brain radioligands

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Renal 123I-MIBG Uptake before and after Live-Donor Kidney Transplantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Nicholas P Hughes
  • Lingyun Xu
  • Carsten H Nielsen
  • Edwin Chang
  • Sharon S Hori
  • Arutselvan Natarajan
  • Samantha Lee
  • Andreas Kjær
  • Kian Kani
  • Shan X Wang
  • Parag Mallick
  • Sanjiv Sam Gambhir
Vis graf over relationer

BACKGROUND AND OBJECTIVE: To monitor therapies targeted to epidermal growth factor receptors (EGFR) in non-small cell lung cancer (NSCLC), we investigated Peroxiredoxin 6 (PRDX6) as a biomarker of response to anti-EGFR agents.

METHODS: We studied cells that are sensitive (H3255, HCC827) or resistant (H1975, H460) to gefitinib. PRDX6 was examined with either gefitinib or vehicle treatment using enzyme-linked immunosorbent assays. We created xenograft models from one sensitive (HCC827) and one resistant cell line (H1975) and monitored serum PRDX6 levels during treatment.

RESULTS: PRDX6 levels in cell media from sensitive cell lines increased significantly after gefitinib treatment vs. vehicle, whereas there was no significant difference for resistant lines. PRDX6 accumulation over time correlated positively with gefitinib sensitivity. Serum PRDX6 levels in gefitinib-sensitive xenograft models increased markedly during the first 24 hours of treatment and then decreased dramatically during the following 48 hours. Differences in serum PRDX6 levels between vehicle and gefitinib-treated animals could not be explained by differences in tumor burden.

CONCLUSIONS: Our results show that changes in serum PRDX6 during the course of gefitinib treatment of xenograft models provide insight into tumor response and such an approach offers several advantages over imaging-based strategies for monitoring response to anti-EGFR agents.

OriginalsprogEngelsk
TidsskriftCancer biomarkers : section A of Disease markers
Vol/bind22
Udgave nummer2
Sider (fra-til)333-344
Antal sider12
ISSN1574-0153
DOI
StatusUdgivet - 2018

ID: 55063159